对心肌梗塞的离子尾酒疗法通过结构和电力改造的协同调节来治疗心肌梗塞
Yumei Que1,2, Jiaxin Shi3, Zhaowenbin Zhang4,5
1Joint Centre of Translational Medicine The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China.
Exploration (Beijing, China)
|June 28, 2024
概括
使用酸盐,和铜离子的新型离子合疗法有效地逆转心肌梗塞 (MI) 后的心脏重塑. 这种治疗改善了心脏的结构和电气方面,为心脏病发作患者提供了一个有前途的新策略.
科学领域:
- 心血管医学 心血管医学
- 再生医学是一种再生医学.
- 生物材料科学 生物材料科学
背景情况:
- 心肌梗塞 (MI) 是全球主要的死亡原因.
- 针对心脏中风后电气和结构性心脏改造的有效治疗方法仍然有限.
- 同时扭转这些重塑过程对于改善患者的治疗结果至关重要.
研究的目的:
- 研究一种新的"离子尾酒疗法",用于同时治疗心脏电气和结构改造后的心脏电击.
- 为了评估酸盐, (Sr) 和铜 (Cu) 离子的特定组合的疗效.
- 在临床前模型中探索这种离子尾酒的治疗潜力.
主要方法:
- 开发了一种"离子尾酒疗法",包括酸盐, (Sr) 和铜 (Cu) 离子.
- 在心肌梗塞后给临床前模型 (老鼠和迷你猪) 进行治疗.
- 通过测量心脏病发作大小和促进血管生成来评估结构重塑.
- 通过分析后分极化和心脏电生理学异质性来评估电气改造.
主要成果:
- 离子尾酒治疗通过减少心脏病发作的大小显著减弱了结构重塑.
- 该疗法促进了心脏周心脏病和心脏病发作区域的血管新生.
- 电气改造部分逆转,由降低后分极化和最小化电生理学异质性证明.
- 该疗法在老鼠和小猪模型中都表现出有效性.
结论:
- 开发的离子尾酒疗法为治疗心肌梗塞提供了一种新有效的策略.
- 这种方法同时解决了心脏中风后的关键结构和电力心脏改造.
- 该疗法具有显著的临床转化潜力,这是由于其高效率和安全性.
更多相关视频
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.1K
06:15A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.
Published on: June 14, 2015
8.7K
相关概念视频
Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
486
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486
